Gianluca Baio

List of Publications by Year
in descending order

99 papers	4,509 citations	136950 32 h-index	114465 63 g-index
105 all docs	105 docs citations	105 times ranked	7396 citing authors

#	ARTICLE	IF	CITATIONS
1	Value of Information Analysis in Models to Inform Health Policy. Annual Review of Statistics and Its Application, 2022, 9, 95-118.	7.0	14
2	Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges. Pharmacoeconomics, 2022, , 1.	3.3	6
3	Using epidemiological evidence to forecast population need for early treatment programmes in mental health: a generalisable Bayesian prediction methodology applied to and validated for first-episode psychosis in England. British Journal of Psychiatry, 2021, 219, 383-391.	2.8	16
4	Conflating marginal and conditional treatment effects: Comments on â€œAssessing the performance of population adjustment methods for anchored indirect comparisons: A simulation studyâ€• Statistics in Medicine, 2021, 40, 2753-2758.	1.6	16
5	Methods for population adjustment with limited access to individual patient data: A review and simulation study. Research Synthesis Methods, 2021, 12, 750-775.	8.7	25
6	Communication of personalised disease risk by general practitioners to motivate smoking cessation in England: A costâ€effectiveness and research prioritisation study. Addiction, 2021, , .	3.3	2
7	A Bayesian parametric approach to handle missing longitudinal outcome data in trialâ€based health economic evaluations. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 607-629.	1.1	6
8	Summarising salient information on historical controls: A structured assessment of validity and comparability across studies. Clinical Trials, 2020, 17, 607-616.	1.6	18
9	Estimating weekly excess mortality at sub-national level in Italy during the COVID-19 pandemic. PLoS ONE, 2020, 15, e0240286.	2.5	65
10	Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry,the, 2020, 7, 865-874.	7.4	120
11	The Effects of Model Misspecification in Unanchored Matching-Adjusted Indirect Comparison: Results of a Simulation Study. Value in Health, 2020, 23, 751-759.	0.3	11
12	Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. Value in Health, 2020, 23, 734-742.	0.3	51
13	<p>Impact of Being Eligible for Type 2 Diabetes Treatment on All-Cause Mortality and Cardiovascular Events: Regression Discontinuity Design Study</p>. Clinical Epidemiology, 2020, Volume 12, 569-577.	3.0	6
14	Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. Medical Decision Making, 2020, 40, 314-326.	2.4	28
15	Modeling outcomes of soccer matches. Machine Learning, 2019, 108, 77-95.	5.4	18
16	Estimating the Expected Value of Sample Information across Different Sample Sizes Using Moment Matching and Nonlinear Regression. Medical Decision Making, 2019, 39, 347-359.	2.4	23
17	R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment. Value in Health, 2019, 22, 575-579.	0.3	31
18	A comparative review of network metaâ€analysis models in longitudinal randomized controlled trial. Statistics in Medicine, 2019, 38, 3053-3072.	1.6	4

#	Article	IF	Citations
19	Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity. Neurology, 2019, 92, e1773-e1785.	1.1	37
20	Bayesian modelling for binary outcomes in the regression discontinuity design. Journal of the Royal Statistical Society Series A: Statistics in Society, 2019, 182, 983-1002.	1.1	5
21	Frequentist and <scp>B</scp>ayesian metaâ€regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data. Health Economics (United) Tj ETQq1 1 0.784314 rgBT3Overlo	1.3	
22	A full Bayesian model to handle structural ones and missingness in economic evaluations from individualâ€level data. Statistics in Medicine, 2019, 38, 1399-1420.	1.6	17
23	Incidence and prevalence of diabetes and cost of illness analysis of polycystic ovary syndrome: a Bayesian modelling study. Human Reproduction, 2018, 33, 1299-1306.	0.9	24
24	Statistical Modeling for Health Economic Evaluations. Annual Review of Statistics and Its Application, 2018, 5, 289-309.	7.0	11
25	Efficient Monte Carlo Estimation of the Expected Value of Sample Information Using Moment Matching. Medical Decision Making, 2018, 38, 163-173.	2.4	23
26	Uptake of the English Bowel (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out. European Journal of Cancer, 2018, 103, 267-273.	2.8	49
27	A dynamic Bayesian Markov model for health economic evaluations of interventions in infectious disease. BMC Medical Research Methodology, 2018, 18, 82.	3.1	14
28	Calculating the Expected Value of Sample Information Using Efficient Nested Monte Carlo: A Tutorial. Value in Health, 2018, 21, 1299-1304.	0.3	11
29	A Review of Methods for Analysis of the Expected Value of Information. Medical Decision Making, 2017, 37, 747-758.	2.4	63
30	The association between psychological stress and miscarriage: A systematic review and meta-analysis. Scientific Reports, 2017, 7, 1731.	3.3	111
31	Development and evaluation of a manual for extended brief intervention for alcohol misuse for adults with mild to moderate intellectual disabilities living in the community: The EBIâ€LD study manual. Journal of Applied Research in Intellectual Disabilities, 2017, 30, 42-48.	2.0	9
32	A comparative review of variable selection techniques for covariate dependent Dirichlet process mixture models. Canadian Journal of Statistics, 2017, 45, 254-273.	0.9	12
33	A feasibility randomised controlled trial of extended brief intervention for alcohol misuse in adults with mild to moderate intellectual disabilities living in the community; The EBI-LD study. Trials, 2017, 18, 216.	1.6	17
34	Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy. Pharmacoeconomics, 2017, 35, 163-176.	3.3	9
35	The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget, 2017, 8, 96351-96358.	1.8	203
36	Effectiveness of an intervention to facilitate prompt referral to memory clinics in the United Kingdom: Cluster randomised controlled trial. PLoS Medicine, 2017, 14, e1002252.	8.4	15

#	Article	IF	Citations
37	Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Effectiveness and Resource Allocation, 2017, 15, 11.	1.5	32
38	When Simple Becomes Complicated: Why Excel Should Lose its Place at the Top Table. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000247.	0.1	6
39	Bayesian Cost-Effectiveness Analysis with the R package BCEA. Use R!, 2017, , .	0.2	22
40	BCEAweb: A User-Friendly Web-App to Use BCEA. Use R!, 2017, , 153-166.	0.2	3
41	Probabilistic Sensitivity Analysis Using BCEA. Use R!, 2017, , 93-152.	0.2	0
42	Bayesian Analysis in Health Economics. Use R!, 2017, , 1-22.	0.2	0
43	Variable selection in covariate dependent random partition models: an application to urinary tract infection. Statistics in Medicine, 2016, 35, 1373-1389.	1.6	13
44	Estimating the expected value of partial perfect information in health economic evaluations using integrated nested Laplace approximation. Statistics in Medicine, 2016, 35, 4264-4280.	1.6	34
45	Diagnosis and management of polycystic ovary syndrome in the UK (2004â€"2014): a retrospective cohort study. BMJ Open, 2016, 6, e012461.	1.9	29
46	An Introduction to Handling Missing Data in Health Economic Evaluations. , 2016, , 73-85.		6
47	Approaches to the Estimation of the Local Average Treatment Effect in a Regression Discontinuity Design. Scandinavian Journal of Statistics, 2016, 43, 978-995.	1.4	11
48	Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999â€"2014. BMJ Open, 2016, 6, e011666.	1.9	126
49	Comparison of computer-assisted planning and manual planning for depth electrode implantations in epilepsy. Journal of Neurosurgery, 2016, 124, 1820-1828.	1.6	31
50	Uptake of Bowel Scope (Flexible Sigmoidoscopy) Screening in the English National Programme: the first 14 months. Journal of Medical Screening, 2016, 23, 77-82.	2.3	46
51	A Bayesian nonparametric model for white blood cells in patients with lower urinary tract symptoms. Electronic Journal of Statistics, 2016, 10, .	0.7	1
52	Bayesian regression discontinuity designs: incorporating clinical knowledge in the causal analysis of primary care data. Statistics in Medicine, 2015, 34, 2334-2352.	1.6	28
53	Sample size calculation for a stepped wedge trial. Trials, 2015, 16, 354.	1.6	114
54	Stepped wedge randomised controlled trials: systematic review of studies published between 2010 and 2014. Trials, 2015, 16, 353.	1.6	113

#	ARTICLE	IF	CITATIONS
55	Five questions to consider before conducting a stepped wedge trial. Trials, 2015, 16, 350.	1.6	52
56	Designing a stepped wedge trial: three main designs, carry-over effects and randomisation approaches. Trials, 2015, 16, 352.	1.6	176
57	Value of Information: A Tool to Improve Research Prioritization and Reduce Waste. PLoS Medicine, 2015, 12, e1001882.	8.4	31
58	Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study. BMJ Open, 2015, 5, e007382-e007382.	1.9	43
59	Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study. Value in Health, 2015, 18, 956-968.	0.3	33
60	Health Utilities Lost and Risk Factors Associated With HPV-induced Diseases in Men and Women: The HPV Italian Collaborative Study Group. Clinical Therapeutics, 2015, 37, 156-167.e4.	2.5	26
61	Cost-effectiveness and affordability of community mobilisation through women's groups and quality improvement in health facilities (MaiKhanda trial) in Malawi. Cost Effectiveness and Resource Allocation, 2015, 13, 1.	1.5	35
62	A predictable outcome. Significance, 2015, 12, 11-13.	0.4	1
63	Urinary ATP as an indicator of infection and inflammation of the urinary tract in patients with lower urinary tract symptoms. BMC Urology, 2015, 15, 7.	1.4	25
64	Extended brief intervention to address alcohol misuse in people with mild to moderate intellectual disabilities living in the community (EBI-ID): study protocol for a randomised controlled trial. Trials, 2015, 16, 114.	1.6	5
65	An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis. Pharmacoeconomics, 2015, 33, 355-366.	3.3	83
66	Probabilistic sensitivity analysis in health economics. Statistical Methods in Medical Research, 2015, 24, 615-634.	1.5	88
67	Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. British Journal of Psychiatry, 2014, 205, 436-442.	2.8	325
68	Evidence of bias in the Eurovision song contest: modelling the votes using Bayesian hierarchical models. Journal of Applied Statistics, 2014, 41, 2312-2322.	1.3	17
69	Bayesian models for cost-effectiveness analysis in the presence of structural zero costs. Statistics in Medicine, 2014, 33, 1900-1913.	1.6	14
70	Telomere length in human blastocysts. Reproductive BioMedicine Online, 2014, 28, 624-637.	2.4	16
71	Preformulated implementation intentions to promote colorectal cancer screening: A cluster-randomized trial.. Health Psychology, 2014, 33, 998-1002.	1.6	30
72	Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data. BMJ, The, 2014, 349, g5293-g5293.	6.0	106

#	ARTICLE	IF	CITATIONS
73	A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technology Assessment, 2014, 18, 1-226, v-vi.	2.8	116
74	Spatial and spatio-temporal models with R-INLA. Spatial and Spatio-temporal Epidemiology, 2013, 4, 33-49.	1.7	267
75	Cost-Effectiveness of Enhancing Adherence to Therapy with Blood Pressureâ€"Lowering Drugs in the Setting of Primary Cardiovascular Prevention. Value in Health, 2013, 16, 318-324.	0.3	14
76	Spatial and spatio-temporal models with R-INLA. Spatial and Spatio-temporal Epidemiology, 2013, 7, 39-55.	1.7	233
77	A Novel Method to Value Real Options in Health Care: The Case of a Multicohort Human Papillomavirus Vaccination Strategy. Clinical Therapeutics, 2013, 35, 904-914.	2.5	15
78	Erratum to â€œSpatial and spatio-temporal models with R-INLAâ€•[Spat Spatio-tempor Epidemiol 4 (2013) 33â€"49]. Spatial and Spatio-temporal Epidemiology, 2013, 7, 37.	1.7	1
79	Transparency or Proper Study Valuation Procedures Missed?. Medical Care, 2013, 51, 374-378.	2.4	1
80	The prevalence of primary angle closure glaucoma in European derived populations: a systematic review. British Journal of Ophthalmology, 2012, 96, 1162-1167.	3.9	141
81	Socioeconomic variation in uptake of colonoscopy following a positive faecal occult blood test result: a retrospective analysis of the NHS Bowel Cancer Screening Programme. British Journal of Cancer, 2012, 107, 765-771.	6.4	56
82	Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study. BMJ Open, 2012, 2, e000736.	1.9	7
83	Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases. Medical Care, 2012, 50, 1076-1085.	2.4	18
84	Economic Burden of Human Papillomavirus-Related Diseases in Italy. PLoS ONE, 2012, 7, e49699.	2.5	46
85	Inequalities in the provision of cardiovascular screening to people with severe mental illnesses in primary care. Schizophrenia Research, 2011, 129, 104-110.	2.0	55
86	Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis, 2011, 217, 479-485.	0.8	26
87	Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. International Journal of Epidemiology, 2011, 40, 712-718.	1.9	262
88	Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis. Expert Opinion on Pharmacotherapy, 2011, 12, 257-268.	1.8	8
89	Bayesian hierarchical model for the prediction of football results. Journal of Applied Statistics, 2010, 37, 253-264.	1.3	92
90	A Decision-Theoretic Framework for the Application of Cost-Effectiveness Analysis in Regulatory Processes. Pharmacoeconomics, 2009, 27, 645-655.	3.3	9

#	Article	IF	Citations
91	Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi–state models. Pharmacoepidemiology and Drug Safety, 2008, 17, 260-269.	1.9	15
92	Economic Evaluation of a Bayesian Model to Predict Late-Phase Success of New Chemical Entities. Value in Health, 2007, 10, 377-385.	0.3	7
93	Handling manipulated evidence. Forensic Science International, 2007, 169, 181-187.	2.2	2
94	Object-oriented influence diagram for cost–effectiveness analysis of influenza vaccination in the Italian elderly population. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 293-301.	1.4	8
95	Economic evaluation of HIV treatments: The I.CO.N.A. cohort study. Health Policy, 2005, 74, 304-313.	3.0	13
96	Bayesian cost-effectiveness analysis based on the persistence with antihypertensive treatment. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 227-236.	1.4	1
97	Long-term persistence with antihypertensive drugs in new patients. Journal of Human Hypertension, 2002, 16, 439-444.	2.2	120
98	A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clinical Therapeutics, 2002, 24, 1347-1357.	2.5	96
99	Regression discontinuity designs for time–to–event outcomes: An approach using accelerated failure time models. Journal of the Royal Statistical Society Series A: Statistics in Society, 0, , .	1.1	0